Noninvasive markers of liver steatosis and fibrosis after liver transplantation-Where do we stand?

• 作者: Ivana Mikolasevic Sanja Stojsavljevic Filip Blazic Maja Mijic Delfa Radic-Kristo Toni Juric Nadija Skenderevic Mia Klapan Andjela Lukic Tajana Filipec Kanizaj
• 来源期刊: 世界移植杂志
• 学科: 医学
• 关键词: STEATOSIS FIBROSIS Noninvasive methods Transient elastography Transplantation Nonalcoholic fatty liver disease
• 年，卷（期）: 2021,（3）
• 页码范围: 37-53
• 页数: 17页
• 分类号: R57

摘要

In the last two decades,advances in immunosuppressive regimens have led to fewer complications of acute rejection crisis and consequently improved shortterm graft and patient survival.In parallel with this great success,long-term posttransplantation complications have become a focus of interest of doctors engaged in transplant medicine.Metabolic syndrome(MetS)and its individual components,namely,obesity,dyslipidemia,diabetes,and hypertension,often develop in the post-transplant setting and are associated with immunosuppressive therapy.Nonalcoholic fatty liver disease(NAFLD)is closely related to MetS and its individual components and is the liver manifestation of MetS.Therefore,it is not surprising that MetS and its individual components are associated with recurrent or“de novo”NAFLD after liver transplantation(LT).Fibrosis of the graft is one of the main determinants of overall morbidity and mortality in the post-LT period.In the assessment of post-LT steatosis and fibrosis,we have biochemical markers,imaging methods and liver biopsy.Because of the significant economic burden of post-LT steatosis and fibrosis and its potential consequences,there is an unmet need for noninvasive methods that are efficient and cost-effective.Biochemical scores can overestimate fibrosis and are not a good method for fibrosis evaluation in liver transplant recipients due to frequent post-LT thrombocytopenia.Transient elastography with controlled attenuation parameter is a promising noninvasive method for steatosis and fibrosis.In this review,we will specifically focus on the evaluation of steatosis and fibrosis in the post-LT setting in the context of de novo or recurrent NAFLD.